课题基金 / 基金详情

The Impact of Exempting Medical Providers from Malpractice Liability

The Impact of Exempting Medical Providers from Malpractice Liability
免除医疗服务提供者医疗事故责任的影响
批准号:
10634734
负责人:
MICHAEL D. FRAKES
金额:
$32.33万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
未结题
起止时间:
2015-06-15 至 2025-05-31

项目摘要

项目成果

MICHAEL D. FRAKES的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
OTHER PROJECT INFORMATION – Project Summary/Abstract THE IMPACT OF EXEMPTING MEDICAL PROVIDERS FROM MALPRACTICE LIABILITY Among the most controversial aspects of the U.S. health care system are the impacts of the medical malpractice system on patient treatments and health care costs. Defensive medicine is an unintended effect of the liability system in which physicians order extraneous tests, procedures and other services as a result of fears over medical liability. The debate continues, however, regarding just how large these costs really are. Missing from the literature's attempts to resolve this debate has been a true “treatment” group of medical encounters with respect to which there is no liability recourse at all in the event of negligent care. We aim to further the analysis begun under R01AG049898, in which we drew on institutional features of the Military Health System (MHS) to estimate the effects of immunizing providers from liability, facilitating an unprecedented assessment of the full extent of defensive medicine operating in our system. We propose to continue this research to push the literature beyond its present focus on inpatient care and to place the effects of liability in perspective by comparing liability's effects with other approaches, especially demand-side approaches, to regulating medical encounters. Our focus will be on investigating the impacts of certain policy levers on age-related diseases such as cardiovascular disease, diabetes, and cancer. The proposed continuation will address four aims. First we will explore the impact of medical liability pressure on “high-value” outpatient care, while placing these estimates into perspective by likewise exploring effects on the receipt of “low-value” care (drawing on high- and low-value measures currently emphasized in the medical literature). Second, drawing on a unique feature of the MHS data, we propose to compare the effects on high- and low-value care receipt stemming from the medical liability system – a classic supply-side approach to regulating provider behavior – with those resulting from a classic demand-side approach to regulating the physician-patient relationship: information disclosure to patients. Third, we will place independent emphasis on one of the key dimensions of comparison necessary to execute the liability analysis – that is, the difference in quality and quantity of care provided on the base through a coordinated direct-delivery system with that provided off the base through the MHS's purchased-care system. Fourth, we will explore aspects of each of the above aims specifically in the context of opioid use among the MHS population, while comparing the effects of liability pressure and information disclosure on opioid use with the effects of one of the most oft- discussed stated-based approaches to regulating opioid use: Prescription Drug Monitoring Programs.
期刊论文(4)
专著(0)
科研奖励(0)
会议论文
Is great information good enough? Evidence from physicians as patients.
伟大的信息就足够好吗?来自医生和患者的证据。
DOI: 10.1016/j.jhealeco.2020.102406
发表时间: 2021-01
期刊: Journal of health economics
影响因子: 3.5
作者: [Frakes M, Gruber J, Jena A]
通讯作者: Jena A
Public and Private Options in Practice: The Military Health System.
实践中的公共和私人选择:军事卫生系统。
DOI: 10.1257/pol.20210625
发表时间: 2023
期刊: American economic journal. Economic policy
影响因子: --
作者: [Frakes,MichaelD, Gruber,Jonathan, Justicz,Timothy]
通讯作者: Justicz,Timothy
The Impacts of Enhanced Drug-Patent Examination
The Impact of Exempting Medical Providers from Malpractice Protection
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: